Drugs for reducing antibiotic resistance and killing bacteria
Technology
Betatides are novel synthetic cell-penetrating peptides that attack bacteria in a fundamentally new way. They reduce antibiotic resistance development and act as an antibiotic.
Market
Treatment of skin, lung, prosthetic joint infections and other infections caused by drug-resistant bacteria.
Uniqueness
- Novel mode of action, new target (beta-clamp).
- Broad single agent effects towards priority pathogens (all ESKAPE pathogens).
- Potentiate effect of other antibiotics and no cross-resistance.
- Reduce the development of resistance towards current and future antibiotics.
- Successful studies in animal models of skin and prosthetic joint infection, successful pilot in lung infection.
- Repeated dose toxicity study by i.v. infusion to rats showed no major toxic effects.
Status
- 1st generation betatides in preclinical stage, with patent granted in USA, Canada and several countries in Europe.
- 2nd generation betatides under development.
- Seeking commercial partners and licensees.
